26RFa by the pyroglutamylated RFamide peptide receptor Industry News NanoImaging Services and Cube Biotech

Industry News Orion Biotechnology at the AACR 2023. (April 20 - 21, 2023) Swiss Biotech Day (April 24 - 25, 2023) NEW ASPET 2023 - American Society for Pharmacology

(April 20 - 21, 2023) Swiss Biotech Day (April 24 - 25, 2023) ASPET 2023 - American Society for Pharmacology

July 2022 " Orion Biotechnology and Peptilogics are pursuing AI-driven drug discovery to explore new

Showcases Innovative AI-Driven Drug Design at BRIC AI 2023 Workshop Salipro Biotech AB Celebrates Milestones

Jan Steyaert , scientific director of the VIB-VUB Center for Structural Biology , Vlaams Instituut Biotechnologie Brusle, Brussels, Belgium, has been named the winner of Brandeis’ 24th Jacob and Louise Gabbay Award in Biotechnology of one of the biggest classes of pharmaceutical targets by combining structural biology and advanced biotechnology

Visit in its clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder Orion Biotechnology will be presenting at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024

Joe Clayton from BioTek Instruments talk about automated micro-plate-based methods for quantifying #GPCR

June 2022 "Ottawa, Canada, May 10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development

neutrophils by promoting an alternative-like polarization during bacterial infection Industry News InterAx Biotech's

(April 20 - 21, 2023) NEW Swiss Biotech Day (April 24 - 25, 2023) SLAS Europe 2023 Conference and Exhibition

Peter Banks, Scientific Director at BioTek Instruments! Learn about his career today!

Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics

Biotherapeutics in Idiopathic Pulmonary Fibrosis Former execs from Pfizer obesity drug program have started a new biotech

in Upcoming Investor and Industry Conferences Sosei and IPJ to become Nxera Pharma from April Orion Biotechnology will be at the BIO CEO & Investor Conference Salipro Biotech AB will be at the Oxford Global’s Biologics

December 2021 "Ottawa, Ontario, Canada, Nov. 30, 2021 -- Orion Biotechnology , a clinical stage company

Secures VLAIO Grant Supporting Drug Discovery & Development In Endocrine And Metabolic Diseases How biotech

of Alcohol and Substance Use Disorders AbbVie recruits a GPCR team in Oxford, buying out a fledgling biotech

To solve this industry-wide problem, Orion Biotechnology (Orion) is introducing a novel solution driven technological advances related to the understanding of structure and activation mechanisms of GPCRs, the biotech investment community has injected significant funding into small biotech companies developing novel About Orion Biotechnology Orion’s mission is to unlock the therapeutic potential of previously undruggable For more information, follow Orion Biotechnology on LinkedIn or visit www.orionbiotechnology.com.

pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare than three decades of experience leading sales and marketing operations for both global and domestic biotechnology

December 2021 "Early-stage studies of COVID-19 treatments from the likes of Vir Biotechnology Inc. and While vaccine-makers race to test their shots against the variant, the monoclonal antibody sotrovimab

pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare

GPCRs), intracellular protein complexes and solute carriers, are relevant to immunology indications and rare

Submit your logo design by Nov 1st on the Logo Contest page. You can find more information about them on the Live Talks page and mark your calendar HERE.

December 2021 "Drug development is rarely trivial.

upon modulation of membrane cholesterol and its consequences on membrane dynamics are addressed only rarely

utilized a semi-quantitative multiplex PCR method, which allowed for the detection of both abundant and rare

Acquired hypocalciuric hypercalcemia (AHH) is a rare disease caused by calcium-sensing receptor (CaSR